PP04   Presentation Time: 9:47 AM

It is currently known that the group of intermediate risk of prostate cancer [PC] is heterogeneous and according to the NCCN classification includes 2 subgroups - favorable and unfavorable intermediate risk [UIR]. The optimal scope of therapy was not defined for the UIR subgroup. In particular, there are no unambiguous recommendations about the total radiotherapy dose, as well as on the need and volume of hormone therapy [HT].Purpose: A comparative analysis of the efficacy of external beam radiation therapy [EBRT] and brachytherapy [BT] with or without androgen deprivation therapy [ADT] in UIR PC patients.

Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Vitaly A. Biryukov, Kseniia S. Makarova, Yulia V. Gumenetskaya, Tatyana A. Rodina, Anastasia B. Galitsyna, Elizaveta O. Shchukina, Oleg B. Karyakin, Sergey A. Ivanov, Andrey D. Kaprin Source Type: research